streptomycin

Trade name: kabikinase

Small moleculeapproved

Approved

Feb 18, 1946

Streptomycin is a water-soluble aminoglycoside derived from Streptomyces griseus. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Streptomycin is indicated for the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium). — NCATS

Clinical trial activity

15 trials · 28 clinical orgs · 5 marketing orgs

Phase 1
3
Phase 2
7
Phase 3
5
Phase 4
1

Earliest trial started Jan 1, 1991 (NCT00004689)

Timeline

1940s

  1. Feb 18, 1946

    Upjohn — Earliest FDA Approval

  2. Feb 18, 1946

    Pfizer — Marketing Organization

  3. Feb 18, 1946

    Upjohn — NDA Organization

1990s

  1. Jan 1, 1991

    Earliest Phase 2 Sponsor(trial)

  2. Jun 30, 1998

    X Gen Pharmaceuticals — Marketing Organization

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedFeb 18, 1946

Chemistry & pharmacology

Loading structure…

SMILES

CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]3N=C(N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O
Mol. weight
1457.4 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Black box warning

Sources

Also known as

  • 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside
  • 2,4-diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-o-(2-deoxy-2-methylamino-alpha-l-glucopyranosyl)-3-c-formyl-beta-l-lyxopentanofuranoside
  • agri-strep
  • agri-strep
  • cb-183,315
  • cb-183,315
  • cb-183,315
  • chemform
  • chemform
  • estreptomicina
  • estreptomicina
  • gerox
  • gerox
  • mannosidostreptomycin
  • mannosylstreptomycin
  • nsc-14083
  • nsc-14083
  • strepcen
  • strepcen
  • streptomicina
  • streptomicina
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin
  • streptomycin b
  • streptomycin b
  • streptomycini sulfas
  • streptomycin sulfate
  • streptomycin sulfate
  • streptomycin sulfate
  • streptomycin sulfate
  • streptomyzin
  • streptomyzin
  • streptorex
  • streptorex
  • surotomycin
  • surotomycin
  • surotomycin
  • surotomycin
  • surotomycin
  • vetstrep
  • vetstrep

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04110340Phase 3Oct 1, 2019Hôpital Universitaire Joseph Raseta Befelatanana CHU d'Antananarivo, University of Oxford
NCT02354014Phase 2May 3, 2016Johnson and Johnson
NCT02365623Phase 2Feb 18, 2015Janssen Pharmaceutica NV, Johnson and Johnson
NCT02128308Phase 1Nov 1, 2013Seoul National University
NCT02331823Phase 4Jun 1, 2013Centers for Disease Control and Prevention (CDC), Government of China, Huazhong University of Science and Technology, Zhejiang University
NCT01659437Phase 2/Phase 3 (Phase 3)Dec 1, 2012Drugs for Neglected Diseases Initiative, Government of Benin, Kumasi Centre for Collaborative Research, Kwame Nkrumah University of Science and Technology, National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana, Noguchi Memorial Institute for Medical Research, University of Antwerp, University of Ghana, University of Groningen, World Alliance for Wound and Lymphoedema Care, Switzerland, World Health Organization
NCT01597505Phase 3May 16, 2012Cubist, Merck
NCT01598311Phase 3May 1, 2012Cubist, Merck
NCT01085591Phase 2Apr 1, 2010Cubist
NCT02835118Phase 1Jul 1, 2009Merck
NCT02835105Phase 1Jan 1, 2009Merck
NCT00128466Phase 2/Phase 3 (Phase 3)Aug 1, 2004Centers for Disease Control and Prevention (CDC), Food and Drug Administration, Government of Madagascar, Government of Uganda
NCT00000796N/ANov 2, 1999National Institute of Allergy and Infectious Diseases (NIAID)
NCT00004444N/ANov 1, 1994Food and Drug Administration, University of Illinois at Chicago
NCT00004689Phase 2Jan 1, 1991University of Colorado, Denver
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (28)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit4222009
CubistFor profit3322010
Centers for Disease Control and Prevention (CDC)Government2122004
Food and Drug AdministrationGovernment2121994
Johnson and JohnsonFor profit2212015
Drugs for Neglected Diseases InitiativeAcademic/Hospital1012012
Government of BeninGovernment1012012
Government of ChinaGovernment1012013
Government of MadagascarGovernment1012004
Government of UgandaGovernment1012004
Hôpital Universitaire Joseph Raseta Befelatanana CHU d'AntananarivoAcademic/Hospital1012019
Huazhong University of Science and TechnologyAcademic/Hospital1112013
Janssen Pharmaceutica NVFor profit1012015
Kumasi Centre for Collaborative ResearchAcademic/Hospital1012012
Kwame Nkrumah University of Science and TechnologyAcademic/Hospital1012012
National Buruli ulcer Control Programme, Ghana Health Service, Accra, GhanaAcademic/Hospital1012012
National Institute of Allergy and Infectious Diseases (NIAID)Government1111999
Noguchi Memorial Institute for Medical ResearchAcademic/Hospital1012012
Seoul National UniversityAcademic/Hospital1112013
University of AntwerpAcademic/Hospital1012012
28 organizations
Page 1 / 2

Marketing (6)

OrganizationOrg typeRelationshipDate
Eci Pharmaceuticals LlcFor profitMKTG
Eli LillyFor profitMKTG
PfizerFor profitMKTGFeb 18, 1946
UpjohnFor profitNDAFeb 18, 1946
X Gen PharmaceuticalsFor profitSYNJun 30, 1998
X Gen PharmaceuticalsFor profitMKTGJun 30, 1998